LitCovid-sample-Enju  

PMC:7228307 / 61606-62087 JSONTXT 14 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T644 0-6 RB denotes Rather
T645 7-11 IN denotes than
T646 12-15 CD denotes one
T647 16-20 NN denotes type
T648 21-23 IN denotes of
T649 24-26 NN denotes Fc
T650 27-29 TO denotes to
T651 30-37 VB denotes conquer
T652 38-41 DT denotes all
T653 41-42 -COMMA- denotes ,
T654 43-46 DT denotes the
T655 47-55 JJ denotes combined
T656 56-59 NN denotes use
T657 60-62 IN denotes of
T658 63-76 RB denotes appropriately
T659 77-85 VBN denotes selected
T660 86-90 NNS denotes mAbs
T661 91-96 WP-DOLLAR- denotes whose
T662 97-107 JJ denotes individual
T663 108-118 NNS denotes components
T664 119-122 VBP denotes are
T665 123-131 VBN denotes enhanced
T666 132-135 IN denotes for
T667 136-139 DT denotes the
T668 140-150 NN denotes engagement
T669 151-153 IN denotes of
T670 154-163 JJ denotes different
T671 164-168 NN denotes FcγR
T672 169-176 NNS denotes members
T673 177-180 MD denotes may
T674 181-188 VB denotes utilize
T675 189-197 JJ denotes multiple
T676 198-208 NNS denotes components
T677 209-211 IN denotes of
T678 212-215 DT denotes the
T679 216-224 NN denotes spectrum
T680 225-227 IN denotes of
T681 228-236 NN denotes effector
T682 237-246 NNS denotes responses
T683 247-249 IN denotes on
T684 250-255 NN denotes offer
T685 256-258 IN denotes by
T686 259-262 DT denotes the
T687 263-269 JJ denotes immune
T688 270-276 NN denotes system
T689 278-282 JJ denotes Such
T690 283-293 NN denotes “next‐gen”
T691 294-303 NNS denotes biologics
T692 304-308 MD denotes will
T693 309-314 VB denotes begin
T694 315-317 TO denotes to
T695 318-325 VB denotes realize
T696 326-329 DT denotes the
T697 330-334 JJ denotes full
T698 335-344 NN denotes potential
T699 345-347 IN denotes of
T700 348-361 JJ denotes FcγR‐mediated
T701 362-370 NN denotes antibody
T702 371-377 JJ denotes immune
T703 378-390 NNS denotes therapeutics
T704 391-394 CC denotes and
T705 395-400 VB denotes offer
T706 401-417 JJ denotes transformational
T707 418-424 NN denotes change
T708 425-428 IN denotes for
T709 429-432 DT denotes the
T710 433-442 NN denotes treatment
T711 443-445 IN denotes of
T712 446-457 JJ denotes intractable
T713 458-461 CC denotes and
T714 462-471 JJ denotes incurable
T715 472-480 NNS denotes diseases
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable